German Software Stock News

If you are looking at PUMA and asking whether the current share price reflects the true value of the business, this article is designed to walk you through that question step by step. PUMA's share price recently closed at €22.28, with returns of 0.1% over 7 days, 5.0% over 30 days, a 0.5% decline year to date, and longer term declines of 47.9% over 1 year, 61.8% over 3 years, and 72.3% over 5 years. This may signal that the market is reassessing growth potential and risk. Recent headlines...

Vividion Therapeutics, Bayer’s wholly owned subsidiary, recently published on the cover of the Journal of Medicinal Chemistry its discovery and optimization of VVD-214, a covalent Werner helicase inhibitor now in Phase I trials for MSI-high cancers, including in combination with pembrolizumab. This work showcases Bayer’s use of chemoproteomics and a covalent-first approach to pursue targeted oncology therapies that may diversify and deepen its pharmaceutical pipeline. We’ll now examine how...

Mouser Electronics recently began shipping Infineon Technologies’ new PSOC Edge machine learning microcontrollers, which combine Arm Cortex-M55 processors, M33 coprocessors, and Infineon’s NNLite accelerator to power responsive, low‑power edge AI devices for smart home, robotics, industrial, and HMI applications. An interesting angle is how PSOC Edge’s always-on AI capabilities, coupled with ModusToolbox and DEEPCRAFT Studio support, aim to simplify engineers’ adoption of voice, audio, and...

At CES 2026, Siemens and partners including NVIDIA, Universal Robots, Robotiq, PepsiCo and Commonwealth Fusion Systems announced expanded collaborations to deploy industrial AI, digital twins and adaptive manufacturing, underpinned by Siemens’ new Digital Twin Composer software and an Industrial AI Operating System vision. By combining photorealistic, physics-based digital twins with real-time factory data in live projects like PepsiCo’s U.S. facilities and CFS’s SPARC fusion machine,...

The fresh collaboration between Bayerische Motoren Werke (XTRA:BMW) and QNX on the software backbone for BMW’s upcoming Neue Klasse vehicles is drawing attention, as investors weigh what more advanced, safety-focused vehicle architectures could mean for the stock. See our latest analysis for Bayerische Motoren Werke. Against this backdrop, Bayerische Motoren Werke’s share price is at €93.62, with a 90 day share price return of 7.02%, while the 1 year total shareholder return of 23.79% points...

TAG Immobilien AG recently came under pressure as higher European interest rates pushed up its financing costs and weighed on its residential property valuations in Germany. This rate-driven headwind is especially important for TAG because its focus on affordable housing and relatively high leverage makes its earnings outlook particularly sensitive to funding conditions. Next, we’ll examine how this shift in financing conditions affects TAG Immobilien’s existing investment narrative around...

Beiersdorf has introduced NIVEA Crème Natural Touch in Germany, a new vegan line extension using 99% natural-origin ingredients and a 99.9% biodegradable formula, following six years of research and consumer testing. This reformulation of the company’s flagship product underlines how Beiersdorf is tying its core NIVEA brand directly to its Net Zero 2045 sustainability ambition. We’ll now examine how anchoring NIVEA Crème to a more natural, biodegradable formula could influence Beiersdorf’s...

Bechtle (XTRA:BC8) is back in focus after recent revenue growth and improved cash flow, coupled with a continued €0.70 dividend and reinvestment into AI-enabled consulting, cloud, and security services across Europe. See our latest analysis for Bechtle. The share price at €44.88 sits alongside a 90 day share price return of 18.29%, while the 1 year total shareholder return of 47.96% contrasts with a weaker 5 year total shareholder return of a 16.99% decline. This suggests momentum has...

If you are wondering whether Deutsche Bank's share price still offers value after a strong run, this article will walk through what the current market price might be implying. The stock last closed at €33.81, with returns of 3.2% over 7 days, 8.7% over 30 days, 0.7% year to date and 104.1% over 1 year, which naturally raises questions about how much of the story is already reflected in the price. Recent coverage around Deutsche Bank has focused on its position in European financials and how...

Why recent geopolitical tension matters for Rheinmetall shares President Trump’s intervention in Venezuela has sharpened concerns about global security, drawing fresh investor attention to defense contractors. Rheinmetall (XTRA:RHM), closely linked to Europe’s military spending ambitions, recently saw its share price move 7% higher on this backdrop. See our latest analysis for Rheinmetall. For context, Rheinmetall’s recent 1-day share price return of 9.36% and 7-day return of 14.81% come...

New buy-back program puts Deutsche Telekom’s capital return in focus Deutsche Telekom (XTRA:DTE) has launched a fresh share buy-back program for 2026 after completing its 2025 effort, putting the company’s capital return policy and share count trends back in the spotlight for investors. The 2025 program involved repurchasing about 65.4 million shares, around 1.3% of the share capital. For 2026, the Board has approved up to €2b of buy-backs running from January 5 through year end. Management...

While Befesa S.A. ( ETR:BFSA ) might not have the largest market cap around , it saw a decent share price growth of 13...

Key Insights The considerable ownership by retail investors in Redcare Pharmacy indicates that they collectively have a...

As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...

Evotec stock: recent performance snapshot Evotec (XTRA:EVT) has drawn attention after a difficult past 3 months, with the share price showing a negative total return and a similar pattern over the past year, prompting closer scrutiny from investors. See our latest analysis for Evotec. At a share price of €5.51, Evotec has seen short term momentum cool. A 90 day share price return of an 18.71% decline sits alongside a 1 year total shareholder return showing a 35.44% loss. This points to fading...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Low-cost index funds make it easy to achieve average market returns. But across the board there are plenty of stocks...

Most readers would already be aware that Mineralbrunnen Überkingen-Teinach GmbH KGaA's (FRA:MUT) stock increased...

Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really...

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Electronic industry in Germany, you could be...

Remote operations shift puts Siemens Energy (XTRA:ENR) in focus Recent coverage of Siemens Energy’s rollout of Remote Operations Centers, built around its Omnivise software platform, has drawn attention to how the company is centralizing power plant monitoring and predictive maintenance. See our latest analysis for Siemens Energy. The Remote Operations Center rollout arrives after a strong run in the shares, with a 90 day share price return of 21.59% and a very large 3 year total shareholder...

In late December 2025, flatexDEGIRO changed its legal form and that of flatexDEGIRO Bank from a German stock corporation (AG) to a Societas Europaea (SE), while also expanding its Group Management Board and appointing long-serving executive Jens Möbitz as Chief Operating Officer from January 1, 2026. This shift to an SE structure, combined with strengthening operational leadership in banking and IT, signals an effort to streamline governance across the group and prepare for the planned...

Merck KGaA, Darmstadt, Germany recently reported that China’s NMPA has granted Priority Review approval for pimicotinib, a CSF-1R inhibitor, to treat adult patients with symptomatic tenosynovial giant cell tumor where surgery risks functional limitation or relatively severe morbidity. This first Chemical Drug Class 1 approval in China for TGCT, backed by strong Phase 3 MANEUVER data, adds a differentiated rare-disease therapy to Merck KGaA’s healthcare portfolio in a major market. We’ll now...

Without a clear single catalyst in focus, Allianz (XTRA:ALV) is drawing attention as investors reassess its recent share performance, income profile, and business scale across insurance and asset management activities. See our latest analysis for Allianz. Allianz’s share price at €387.7 has had a relatively steady few weeks, with a 30 day share price return of 5.73% and a 90 day share price return of 6.42%, while the 1 year total shareholder return of 35.26% and 3 year total shareholder...